Rebekka Lencer
TitelZitiert vonJahr
Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial.
GDE 41. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP ...
Lancet 371 (9618), 1085-1097, 2008
11352008
Pharmacological treatment effects on eye movement control
JL Reilly, R Lencer, JR Bishop, S Keedy, JA Sweeney
Brain and cognition 68 (3), 415-435, 2008
2692008
Eye tracking dysfunction is a putative phenotypic susceptibility marker of schizophrenia and maps to a locus on chromosome 6p in families with multiple occurrence of the disease
V Arolt, R Lencer, A Nolte, B Müller‐Myhsok, S Purmann, M Schürmann, ...
American journal of medical genetics 67 (6), 564-579, 1996
2361996
Clinical spectrum of homozygous and heterozygous PINK1 mutations in a large German family with Parkinson disease: role of a single hit?
K Hedrich, J Hagenah, A Djarmati, A Hiller, T Lohnau, K Lasek, ...
Archives of Neurology 63 (6), 833-838, 2006
1262006
Neurophysiology and neuroanatomy of smooth pursuit in humans
R Lencer, P Trillenberg
Brain and cognition 68 (3), 219-228, 2008
1082008
Correlates of cognitive impairment in first episode schizophrenia: the EUFEST study
FWW 38. Galderisi S, Davidson M, Kahn RS, Mucci A, Boter H, Gheorghe MD ...
Schizophrenia Research 115, 104-114, 2009
1012009
Primary focal dystonia: evidence for distinct neuropsychiatric and personality profiles
R Lencer, S Steinlechner, J Stahlberg, H Rehling, M Orth, T Baeumer, ...
Journal of Neurology, Neurosurgery & Psychiatry 80 (10), 1176-1179, 2009
902009
Cortical mechanisms of smooth pursuit eye movements with target blanking. An fMRI study
R Lencer, M Nagel, A Sprenger, S Zapf, C Erdmann, W Heide, F Binkofski
European Journal of Neuroscience 19 (5), 1430-1436, 2004
902004
Mutations in DYT1: extension of the phenotypic and mutational spectrum
K Kabakci, K Hedrich, JC Leung, M Mitterer, P Vieregge, R Lencer, ...
Neurology 62 (3), 395-400, 2004
852004
Morphological basis for the spectrum of clinical deficits in spinocerebellar ataxia 17 (SCA17)
K Lasek, R Lencer, C Gaser, J Hagenah, U Walter, A Wolters, N Kock, ...
Brain 129 (9), 2341-2352, 2006
812006
Hyperprolactinemia in antipsychotic-naive patients with first-episode psychosis
FWW 23. Riecher-Rössler A, Rybakowski JK, Pflueger MO, Beyrau R, Kahn RS ...
Psychological Medicine 43 (12), 2571-82, 2013
782013
Co-occurrence of affective and schizophrenia spectrum disorders with PINK1 mutations
S Steinlechner, J Stahlberg, B Völkel, A Djarmati, J Hagenah, A Hiller, ...
Journal of Neurology, Neurosurgery & Psychiatry 78 (5), 532-535, 2007
742007
Nonmotor symptoms in genetic Parkinson disease
M Kasten, L Kertelge, N Brüggemann, J van der Vegt, A Schmidt, V Tadic, ...
Archives of neurology 67 (6), 670-676, 2010
692010
Eye movements and psychiatric disease
P Trillenberg, R Lencer, W Heide
Current opinion in neurology 17 (1), 43-47, 2004
692004
Parametric modulation of cortical activation during smooth pursuit with and without target blanking. An fMRI study
M Nagel, A Sprenger, S Zapf, C Erdmann, D Kömpf, W Heide, F Binkofski, ...
Neuroimage 29 (4), 1319-1325, 2006
652006
Schizophrenia spectrum disorders and eye tracking dysfunction in singleton and multiplex schizophrenia families
R Lencer, K Trillenberg-Krecker, E Schwinger, V Arolt
Schizophrenia Research 60 (1), 33-45, 2003
552003
Testing for linkage of eye tracking dysfunction and schizophrenia to markers on chromosomes 6, 8, 9, 20, and 22 in families multiply affected with schizophrenia
V Arolt, R Lencer, S Purmann, M Schürmann, B Müller‐Myhsok, K Krecker, ...
American journal of medical genetics 88 (6), 603-606, 1999
551999
Reduced neuronal activity in the V5 complex underlies smooth-pursuit deficit in schizophrenia: evidence from an fMRI study
R Lencer, M Nagel, A Sprenger, W Heide, F Binkofski
Neuroimage 24 (4), 1256-1259, 2005
522005
Eye-tracking dysfunction (ETD) in families with sporadic and familial schizophrenia
R Lencer, CP Malchow, K Trillenberg-Krecker, E Schwinger, V Arolt
Biological Psychiatry 47 (5), 391-401, 2000
512000
Botulinum toxin as an effective treatment of clozapine-induced hypersalivation
KG Kahl, J Hagenah, S Zapf, P Trillenberg, C Klein, R Lencer
Psychopharmacology 173 (1-2), 229-230, 2004
442004
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20